Payment overview · 2025
General Payments
$312.09
12 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher Robert Buttelman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTHRIDGE, CA · NPI 1437128840
Verified facts
What the public records show
CMS Open Payments records show Christopher Robert Buttelman, MD received $312.09 in general payments during 2025 across 12 reported records.
Amgen Inc. accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Xifaxan.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $129.56 | 41.5% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $35.78 | 11.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.91 | 10.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.25 | 8.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.22 | 8.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.61 | 7.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.01 | 6.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.75 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.09 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $107.27 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $107.27 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $35.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.91 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 77 |
| Metformin Hcl | Metformin Hcl | 248 | 76 |
| Losartan Potassium | Losartan Potassium | 237 | 60 |
| Lisinopril | Lisinopril | 174 | 52 |
| Furosemide | Furosemide | 162 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 42 |
| Omeprazole | Omeprazole | 148 | 39 |
| Alprazolam | Alprazolam | 144 | 23 |
| Gabapentin | Gabapentin | 138 | 40 |
| Eliquis | Apixaban | 135 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 31 |
| Simvastatin | Simvastatin | 133 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 27 |
| Lorazepam | Lorazepam | 106 | 35 |
| Carvedilol | Carvedilol | 95 | 23 |
| Potassium Chloride | Potassium Chloride | 94 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 28 |
| Azithromycin | Azithromycin | 83 | 65 |
| Tramadol Hcl | Tramadol Hcl | 79 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 27 |
| Clonazepam | Clonazepam | 74 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 21 |
| Trazodone Hcl | Trazodone Hcl | 73 | 23 |
| Benazepril Hcl | Benazepril Hcl | 68 | 17 |
| Digoxin | Digoxin | 66 | suppressed |
| Naproxen | Naproxen | 66 | 22 |
| Clonidine Hcl | Clonidine Hcl | 63 | 18 |
| Sertraline Hcl | Sertraline Hcl | 62 | 14 |
| Glipizide | Glipizide | 55 | 16 |
| Levetiracetam | Levetiracetam | 55 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 16 |
| Atenolol | Atenolol | 49 | 12 |
| Temazepam | Temazepam | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 21 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 32 |
| Ondansetron Odt | Ondansetron | 42 | 25 |
| Baclofen | Baclofen | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 31 |
| Finasteride | Finasteride | 39 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 11 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 27 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Linzess | Linaclotide | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.09 · 12 records | Amgen Inc. | Cologuard Collection Kit, ENTRESTO, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, LifeVest, OTEZLA, REPATHA, TEZSPIRE, VOQUEZNA, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error